Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020)

<b>Background:</b> Despite advances in glioblastoma (GBM) management, median overall survival (mOS) remains poor, and multi-modal disparities persist. We sought to evaluate trends in GBM treatment and survival outcomes from 2005-2020, with a focus on sociodemographic and geographic disparities. <b>Methods:</b> We conducted a retrospective US-based cohort study using the National Cancer Database (NCDB), stratifying study period into four intervals (2005-2008, 2009-2012, 2013-2016, and 2017-2020). Logistic regression was used to identified predictors of receipt of combination surgery, radiation, and chemotherapy (Sx+RT+Chemo). Kaplan-Meier and multivariable Cox proportional hazards approaches were used to assess mOS. <b>Results:</b> A total of 111,955 adults with GBM were included. From 2005-2008 to 2017-2020, mOS increased from 7.8 to 9.5 months, with geographically unequal gains in survival across the US. In multivariable logistic regression model adjusting for known confounders, combined Sx+RT+Chemo was less likely to be received by female patients (OR 0.90, 95% CI 0.88-0.92) vs. male, non-White patients (OR 0.90, 95% CI 0.86-0.94) vs. White, patients treated at community hospitals (OR: 0.78, 95% CI 0.76-0.80) vs. academic centers, publicly-insured patients (OR 0.74, 95% CI 0.71-0.76) or uninsured patients (OR 0.54, 95% CI 0.50-0.58) vs. privately-insured, and patients living in the South (OR 0.88, 95% CI 0.85-0.91), Midwest (OR 0.83, 95% CI 0.80-0.86), and West (OR 0.85, 95% CI 0.81-0.88) compared to the Northeast. In multivariable Cox regression, significantly poorer survival was seen amongst non-metropolitan patients, community-based hospital patients, and publicly-insured and uninsured patients (vs. privately-insured), despite adjusting for prognostic factors. <b>Conclusions:</b> Only modest improvement in mOS of GBM patients has occurred across 2005-2020, with persistent disparities linked to sociodemographic and structural factors, whose redressal warrants multi-pronged efforts.

Authors

Institutions

Publication Details

Journal
Brain Sciences
Published
2025-05-23
DOI
https://doi.org/10.3390/brainsci15060556
Citations
1
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020)

Ahmad Ozair, Zouina Sarfraz, Manmeet S. Ahluwalia, Alireza Mansouri et al.
1 citations
Brain Sciences
Glioma Diagnosis and Treatment
1.63
article

Association of Health Disparities with Glioblastoma Treatment and Outcomes: Insights from a 15-Year National Cohort (2005–2020)

Ahmad Ozair, Zouina Sarfraz, Manmeet S. Ahluwalia, Alireza Mansouri, Diya Jayram, Shreyas Bellur, Arun Maharaj, Lydia Hodgson
article en
1 citations

Abstract

<b>Background:</b> Despite advances in glioblastoma (GBM) management, median overall survival (mOS) remains poor, and multi-modal disparities persist. We sought to evaluate trends in GBM treatment and survival outcomes from 2005-2020, with a focus on sociodemographic and geographic disparities. <b>Methods:</b> We conducted a retrospective US-based cohort study using the National Cancer Database (NCDB), stratifying study period into four intervals (2005-2008, 2009-2012, 2013-2016, and 2017-2020). Logistic regression was used to identified predictors of receipt of combination surgery, radiation, and chemotherapy (Sx+RT+Chemo). Kaplan-Meier and multivariable Cox proportional hazards approaches were used to assess mOS. <b>Results:</b> A total of 111,955 adults with GBM were included. From 2005-2008 to 2017-2020, mOS increased from 7.8 to 9.5 months, with geographically unequal gains in survival across the US. In multivariable logistic regression model adjusting for known confounders, combined Sx+RT+Chemo was less likely to be received by female patients (OR 0.90, 95% CI 0.88-0.92) vs. male, non-White patients (OR 0.90, 95% CI 0.86-0.94) vs. White, patients treated at community hospitals (OR: 0.78, 95% CI 0.76-0.80) vs. academic centers, publicly-insured patients (OR 0.74, 95% CI 0.71-0.76) or uninsured patients (OR 0.54, 95% CI 0.50-0.58) vs. privately-insured, and patients living in the South (OR 0.88, 95% CI 0.85-0.91), Midwest (OR 0.83, 95% CI 0.80-0.86), and West (OR 0.85, 95% CI 0.81-0.88) compared to the Northeast. In multivariable Cox regression, significantly poorer survival was seen amongst non-metropolitan patients, community-based hospital patients, and publicly-insured and uninsured patients (vs. privately-insured), despite adjusting for prognostic factors. <b>Conclusions:</b> Only modest improvement in mOS of GBM patients has occurred across 2005-2020, with persistent disparities linked to sociodemographic and structural factors, whose redressal warrants multi-pronged efforts.

Brain SciencesVol. 15(6)
University of Maryland, Baltimore (US), Baptist Hospital of Miami (US), Florida International University (US), Baptist Health South Florida (US), Penn State Milton S. Hershey Medical Center (US)
Openalex Percentile: Top 17%
Glioma Diagnosis and Treatment
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.